West Pharmaceutical Gains as Morgan Stanley Hikes Price Target to $400

Key Facts

1Morgan Stanley upgraded West Pharmaceutical Services to Overweight and raised its price target from $365 to $400.

2The company's Q2 2026 revenue of $872.3 million exceeded analyst estimates.

In a move reflecting growing optimism in the medical instruments and supplies sector, West Pharmaceutical Services received a significant boost following an analyst upgrade. Morgan Stanley upgraded the stock to Overweight and raised its price target from $365 to $400. This positive shift follows a robust Q2 2026 performance where the company reported revenue of $872.3 million, effectively exceeding consensus analyst estimates.

The upgrade comes as the stock trades near its 52-week high, signaling strong institutional confidence. Per market data, while West Pharmaceutical gains momentum, major financial peers showed steady levels as of the September 23, 2026 close, with Morgan Stanley (MS) at $198.39, JPMorgan (JPM) at $337.53, and Goldman Sachs (GS) at $936.36.

WST shares stood at $375.87 at the close of September 23, 2026, positioned within striking distance of its annual peak. Investors are now watching for the stock to test the new $400 valuation ceiling. With no major upcoming economic catalysts scheduled in the immediate calendar, market attention remains fixed on whether the company's operational guidance will translate into further earnings beats.